about
Development of a new vaccine for the prevention of Lassa fever.Arenavirus reverse genetics: new approaches for the investigation of arenavirus biology and development of antiviral strategiesAnimal Models for the Study of Rodent-Borne Hemorrhagic Fever Viruses: Arenaviruses and HantavirusesAdvanced vaccine candidates for Lassa feverNative functionality and therapeutic targeting of arenaviral glycoproteinsEnvelope exchange for the generation of live-attenuated arenavirus vaccinesLassa fever virus peptides predicted by computational analysis induce epitope-specific cytotoxic-T-lymphocyte responses in HLA-A2.1 transgenic mice.Sindbis Virus Vectors Designed To Express a Foreign Protein as a Cleavable Component of the Viral Structural PolyproteinRodent-borne diseases and their risks for public healthA live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses.Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys.T cell-dependence of Lassa fever pathogenesis.VaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever.Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses.Comparative analysis of disease pathogenesis and molecular mechanisms of New World and Old World arenavirus infections.Polyfunctional CD4+ T cell responses to a set of pathogenic arenaviruses provide broad population coverageCoverage of related pathogenic species by multivalent and cross-protective vaccine design: arenaviruses as a model systemComparative pathogenesis and systems biology for biodefense virus vaccine development.Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever.LCMV-mediated hepatitis in rhesus macaques: WE but not ARM strain activates hepatocytes and induces liver regeneration.Towards a human Lassa fever vaccine.Three minimal sequences found in Ebola virus genomes and absent from human DNA.Reverse genetics approaches to combat pathogenic arenavirusesPathogenesis of arenavirus hemorrhagic fevers.Vaccination strategies against highly pathogenic arenaviruses: the next steps toward clinical trialsTranscriptome analysis of human peripheral blood mononuclear cells exposed to Lassa virus and to the attenuated Mopeia/Lassa reassortant 29 (ML29), a vaccine candidatePathogenesis of Lassa fever in cynomolgus macaques.Identification of protective Lassa virus epitopes that are restricted by HLA-A2.Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus.Genomic profiling of host responses to Lassa virus: therapeutic potential from primate to manShedding dynamics of Morogoro virus, an African arenavirus closely related to Lassa virus, in its natural reservoir host Mastomys natalensisYellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs.Functional interferon system is required for clearance of lassa virus.Enhanced Efficacy of a Codon-Optimized DNA Vaccine Encoding the Glycoprotein Precursor Gene of Lassa Virus in a Guinea Pig Disease Model When Delivered by Dermal Electroporation.A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunityArenavirus Glycan Shield Promotes Neutralizing Antibody Evasion and Protracted Infection.Lassa virus infection in experimentally infected marmosets: liver pathology and immunophenotypic alterations in target tissuesLassa virus.Exotic emerging viral diseases: progress and challenges.Evaluation in nonhuman primates of vaccines against Ebola virus.
P2860
Q21563440-CBCB2AC7-B436-490D-8E52-39267240BCA6Q24599295-A8EF2C15-59D1-4BE3-9563-32F12D689C0BQ26798695-8FF55E82-958E-4AC1-9974-A60F3FBD317AQ26823627-FCA9E760-66E2-4E50-A2E9-6ED9293F5FC8Q26827679-1C7796BB-78B1-4A33-B220-B078401EB47EQ27320211-57868621-2F17-4FA5-B360-C8255F2C8728Q27472584-E70826E0-69B3-485E-AC70-2237C7406242Q27473478-17B998FE-83F8-4B73-8809-40BE88921C7AQ28249580-FF9BE864-E9AD-4EE3-BE23-9250C9B2A858Q33226128-8BAD809F-6C46-4290-934E-4B0C4AEE4B69Q33383772-A729F178-F8CE-4389-B99C-6C2AAC545FF1Q33548699-F3FBD528-38D8-409C-A5EF-3A5B7CF7237EQ33723534-90EB07C8-9B30-4EF3-A3DC-87079FEFF2AFQ33850032-37E36DEC-F2A3-4E2A-B2D4-AA9F26E431D7Q33887328-7F07A66E-5468-47D8-BFFC-7AD5A52BE4B0Q33892499-049C0C81-1D70-4A70-92A6-7814FADD2536Q33909096-07531017-FCE1-47BB-B695-637C4CA8AD88Q33959989-82E079B2-E16E-4CFD-B71E-9414DA1752AEQ34322342-230AEACE-7C9D-489C-A2D2-EBA50FB36E36Q34338137-4CB6A428-04F4-442F-AFC5-88E274E45DDBQ34394797-0C787230-2585-440B-BF40-E6A6250E77D2Q34470151-98DC2550-F6D6-4C36-A53C-03380CBB840CQ34596958-B3C2EB07-6FB0-4E2A-846F-BD4D49260250Q34625899-EEEDA8EC-9871-4F6E-A2B7-A846D28D1977Q34671806-96A39CA8-3EEB-4B2A-B33C-747F1D7376A4Q34999818-1B3ED054-1426-4AE2-AE64-B793048409FAQ35014564-950F64C9-C8A0-4FA8-9F90-0B9D224642BCQ35024149-15E4F8F9-4B4A-49C9-9853-93FC84A95165Q35140402-09D0DC07-1542-49C6-82A4-1477001DFA6BQ35248863-150FF1EE-C031-4989-85C6-67889D45F0C4Q35663703-A141FBD9-8F98-4E77-9304-A793AE49865DQ35814851-8842462C-E4A8-4890-B917-C35ED21EA8F5Q35826301-C9EB6251-4C21-48BD-9A7B-AA69987FF0E1Q35826698-0E3D9A2C-9428-4A3D-B8E8-00BE22FC3E35Q35842756-7DC205E0-85A6-456D-BDBC-A3437D65B412Q35847032-553E2F1F-E67A-47D7-A17B-D34D942F5BAAQ35857273-7B09CD07-3022-41E4-A00D-813882FC406AQ35919691-3EA3289F-00DB-419A-849B-CD39DA0CA88BQ35971398-4794B15C-1668-46FA-AEFA-9806839F1F7BQ36015461-9D101A2A-3906-4849-A8F1-093C81D35357
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Effective vaccine for lassa fever.
@ast
Effective vaccine for lassa fever.
@en
type
label
Effective vaccine for lassa fever.
@ast
Effective vaccine for lassa fever.
@en
prefLabel
Effective vaccine for lassa fever.
@ast
Effective vaccine for lassa fever.
@en
P2093
P2860
P921
P1433
P1476
Effective vaccine for lassa fever.
@en
P2093
J B McCormick
L Hutwagner
S P Fisher-Hoch
P2860
P304
P356
10.1128/JVI.74.15.6777-6783.2000
P577
2000-08-01T00:00:00Z